1. In Vivo

GE Acquires Clarient To Anchor Its Molecular IVD Business

GE is buying Clarient, which provides molecular cancer tests. It intends to make Clarient the cornerstone around which it builds out a molecular in vitro diagnostics business, combining Clarient with its own diagnostic imaging expertise to give it a full suite of triage and cancer diagnostic capabilities. In some ways, it could solve GE's long-standing issue of how to innovate in healthcare and move into high-value businesses without taking on the risks and timelines of pharma-style R&D.

With cancer diagnosis and characterization in the vanguard of molecular diagnostics development and investment, General Electric Co.'s GE Healthcare division's choice of the area for its first major external investment in molecular IVD test content certainly appears rational. In October, GE made a tender offer of slightly over $580 million for Clarient Inc., which provides laboratory tests using important clinically validated cancer molecular markers including BRAF, EGFr, and KRAS. [See Deal] GE intends to make Clarient the cornerstone around which it builds out a molecular in vitro diagnostics (IVD) business.

Clarient's laboratory utilizes most of the standard cancer testing technologies including immunohistochemistry, flow cytometry, FISH, and imaging. GE Healthcare, working...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.